• VolitionRx Limited to Present at 9th Annual Biotech Showcase Conference

  • VolitionRx Limited to Attend Citi 2016 Global Healthcare Conference

  • VolitionRx Limited to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2016

  • VolitionRx Limited Announces Third Quarter 2016 Financial Results and Business Update

  • VolitionRx Limited Schedules Third Quarter 2016 Earnings Conference Call and Business Update

  • VolitionRx Limited and Hvidovre Hospital Begin Large Prospective Clinical Study

  • VolitionRx Limited Announces Acquisition of New Belgian Facility and Appointment of COO to Belgian Volition

  • VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriter

  • Triage Blood Test Data Presented to Leading International Experts at the World Endoscopy Organization's Colorectal Cancer Screening Committee

  • Data Presented at ESMO 2016 Demonstrates that VolitionRx Limited's Novel Blood Test for Colorectal Cancer Potentially Reduces the Need for Colonoscopy Referral by 25%

  • VolitionRx Limited Announces Closing of Public Offering of Common Stock

  • VolitionRx Limited Announces Pricing of Public Offering of Common Stock

  • VolitionRx Limited Announces Proposed Public Offering of Common Stock

  • VolitionRx to Attend Several Conferences in September

  • Volition's Nu.Q Triage Colorectal Cancer Screening Test Expected to Reduce Colonoscopy Referral by 25 Percent

  • VolitionRx Schedules Product Launch Update Conference Call for Tuesday, September 6, 2016 at 8:30 am ET

  • VolitionRx Announces Second Quarter 2016 Financial Results and Business Update

  • VolitionRx Schedules Second Quarter 2016 Earnings Conference Call and Business Update for Thursday, August 11, 2016 at 8:30am ET

  • VolitionRx Engages Edison Advisors as Investor Relations Counsel

  • VolitionRx Granted Fourth U.S. Patent

  • VolitionRx Appoints Dr. Edward Futcher to Board of Directors

  • VolitionRx Publishes Study Confirming Stability of Circulating Cell-Free Nucleosomes as Biomarkers for Cancer Diagnostic Blood Tests

  • VolitionRx to Present at Two Upcoming Conferences in June

  • VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting

  • VolitionRx Announces First Quarter 2016 Financial Results and Business Update

  • VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer

  • VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET

  • VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test

  • VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer

  • VolitionRx to Participate in 2016 Morgan Stanley Healthcare Insight Series

  • VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study

  • VolitionRx Announces CE Marks for Two NuQ® Blood Assays for Detection of Colorectal Cancer

  • VolitionRx Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full

  • VolitionRx Announces Pricing of Public Offering of Common Stock

  • VolitionRx Announces Proposed Public Offering of Common Stock

  • VolitionRx Announces Full Year 2015 Financial Results and Business Update

  • VolitionRx Schedules Full-Year 2015 Earnings Conference Call and Business Update for Friday, March 11, 2016 at 8:30am ET

  • Preliminary Data Demonstrates 86% Accuracy in Detecting Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease

  • VolitionRx Demonstrates 75% Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ® Blood Test

  • VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection

  • /C O R R E C T I O N -- VolitionRx Ltd/

  • VolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK

  • VolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests

  • VolitionRx Releases Annual Shareholder Update Letter

  • VolitionRx Announces Dr. Jason Terrell's Transition to Full-Time Status as Chief Medical Officer and Head of U.S. Operations

  • VolitionRx Granted Its Third U.S. Patent

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus